Nazanin Majd, M.D., Ph.D.

Peer-Reviewed Articles

1. Harrison RA, Majd N, Johnson MO, Urbauer DL, Puduvalli VK, Khasraw M.. Characterization of Industry Relationships in Oncology. Cancer 40(16), 2023. PMID: 37227811.
2. Rodriguez A, Kamiya-Matsuoka C, Majd NK.. The Role of Immunotherapy in the Treatment of Rare Central Nervous System Tumors. Current Oncology 30(6):5279-5298, 2023. PMID: 37366884.
3. Gregory TA, Mastall M, Lin H, Hess KR, Yuan Y, Garcia MM, Fuller GN, Alfaro KD, Gule-Monroe MK, Huse JT, Khatua S, Rao G, Sandberg DI, Wefel JS, Yeboa DN, Paulino AC, McGovern SL, Zaky W, Mahajan A, Suki D, Weathers S, Harrison RA, de Groot JF, Puduvalli VK, Penas-Prado M, Majd NK.. Characterization of recurrence patterns and outcomes of medulloblastoma in adults: The University of Texas MD Anderson Cancer Center experience. Neuro Oncology Advances 5(1), 2023.
4. Gregory TA, Williford GL, Maronge JM, Alfaro K, Fuller GN, Groot J, Puduvalli VK, Ballester LY, Majd NK.. An expedited strategy for accurate and timely integrated molecular diagnosis of gliomas. Neuro-Oncology, 2023. PMID: 36723868.
5. Pushan D, Veerakumar B, de Groot JF, Majd NK.. Preclinical Models of Low-Grade Gliomas. Cancers 15(3), 2023. PMID: 36765553.
6. de Groot J, Ott M, Wei J, Kassab C, Fang D, Najem H, O'Brien BJ, Weathers SP, Kamiya Matsouka C, Majd NK, Harrison RA, Fuller GN, Huse JT, Long JP, Sawaya R, Rao G, MacDonald TJ, Priebe W, DeCuypere M, Heimberger AB.. A first-in-human Phase I trial of the oral p-STAT3 inhibitor WP1066 in patients with recurrent malignant glioma. CNS Oncology 11(2):CNS87, 2022. PMID: 35575067.
7. Dono A, Alfaro-Munoz K, Yan Y, Lopez-Garcia CA, Soomro Z, Williford G, Takayasu T, Robell L, Majd NK, de Groot J, Esquenazi J, Kamiya-Matsuoka C, Ballester LY.. Molecular, Histological, and Clinical Characteristics of Oligodendrogliomas: A Multi-Institutional Retrospective Study. Neurosurgery 90(5):515-522, 2022. PMID: 35179134.
8. Khan S, Mahalingam R, Sen S, Martinez-Ledesma E, Khan A, Gandy K, Lang FF, Sulman EP, Alfaro-Munoz K.D, Majd NK, Balasubramaniyan V, de Groot JF.. Intrinsic Interferon Signaling Regulates the Cell Death and Mesenchymal Phenotype of Glioblastoma Stem Cells. Cancers 13(21):5284, 2021.
9. Majd NK, Mastall M, Lin H, Dibaj SS, Hess KR, Yuan Y, Garcia MM, Fuller GN, Alfaro KD, Gule-Monroe MK, Huse JT, Khatua S, Rao G, Sandberg DI, Wefel JS, Yeboa DN, Paulino AC, McGovern SL, Zaky W, Mahajan A, Suki D, Weathers S, Harrison RA, De Groot JF, Puduvalli VK, Penas-Prado M.. Clinical Characterization of Adult Medulloblastoma and The Effect of First-line Therapies on Outcome; The MD Anderson Cancer Center Experience. Neuro-Oncology Advances, 2021.
10. Majd NK, Yap TA, Koul D, Balasubramaniyan V, Li X, Khan S, Gandy KS, Yung WKA, de Groot JF.. The promise of DNA damage response inhibitors for the treatment of glioblastoma. Neuro-Oncology Advances 3(1), 2021.
11. Majd NK, Waguespack SG, Janku F, Fu S, Penas-Prado M, Xu M, Alshawa A, Kamiya-Matsuoka C, Raza SM, McCutcheon IE, Naing A.. Efficacy of pembrolizumab in patients with pituitary carcinoma: report of four cases from a phase II study. Journal for Immunotherapy Cancer 8(2), 2020. PMID: 33427689.
12. Park SY, Mittal S, Dong J, Jeong K, Martinez-Ledesma E, Piao Y, Khan S, Henry V, Verhaak RG, Majd NK, Balasubramaniyan V, De Groot JF.. Depletion of CLK2 sensitizes glioma stem-like cells to PI3K/mTOR and FGFR inhibitors. American Journal of Cancer Research 10(11):3765-3783, 2020. PMID: 33294266.
13. Ferguson SD, Hodges TR, Majd NK, Alfaro-Munoz K, Al-Holou WN, Suki D, de Groot JF, Fuller GN, Xue L, Li M, Jacobs C, Rao G, Colen RR, Xiu J, Verhaak R, Spetzler D, Khasraw M, Sawaya R, Long JP, Heimberger AB.. A validated integrated clinical and molecular glioblastoma long-term survival-predictive nomogram. Neuro-Oncology Advances 3(2), 2020. PMID: 33426529.
14. Trevino CR, Paulino AC, Kumar VA, Majd N, Penas-Prado M.. Radiation-induced central demyelination, report of a rare subacute complication and review of the literature. Journal Neuroimmunology and Neuroinflammation, 2020.
15. Nantavithya C, Paulino AC, Liao K, McGovern SL, Grosshans DR, McAleer MF, Woodhouse KD, Khatua S, Chintagumpala MM, Majd NK, Yeboa DN.. Development of Second Primary Tumors and Outcomes in Medulloblastoma by Treatment Modality: A Surveillance, Epidemiology and End Results Analysis. Pediatric Blood & Cancer 67(8), 2020. PMID: 32453481.
16. Aaroe AE, Majd NK, Weathers SP, De Groot JF.. Potential neurologic and oncologic implications of the novel coronavirus. Neuro-Oncology 22(7):1050-1051, 2020. PMID: 32296828.
17. Weathers SP, Penas-Prado M, Pei BL, Ling X, Kassab C, Banerjee P, Bdiwi M, Chaim H, Alsuliman A, Shanley M, de Groot JF, O'Brien BJ, Harrison RA, Majd NK, Kamiya-Matsuoka C, Fuller GF, Huse JT, Chi L, Rao G, Weinberg JS, Lang FF, Sawaya R, Shpall EJ, Rezvani K, Heimberger AB.. Glioblastoma-mediated Immune Dysfunction Limits CMV-specific T cells and Therapeutic Responses: Results from a Phase I/II Trial. Clinical Cancer Research, 2020.
18. Khan S, Mittal S, McGee K, Alfaro-Munoz KD, Majd N, Balasubramaniyan V, de Groot JF.. Role of Neutrophils and Myeloid-Derived Suppressor Cells in Glioma Progression and Treatment Resistance. International Journal of Molecular Sciences 21(6), 2020.
19. Naffouje R, Grover P, Yu H, Sendilnathan A, Wolfe K, Majd N, Smith EP, Takeuchi K, Senda T, Kofuji S, Sasaki AT. Anti-Tumor Potential of IMP Dehydrogenase Inhibitors: A Century-Long Story. Cancers (Basel) 11(9), 2019. PMID: 31514446.
20. Yoshino H, Yin G, Kawaguchi R, Popov KI, Temple B, Sasaki M, Kofuji S, Wolfe K, Kofuji K, Okumura K, Randhawa J, Malhotra A, Majd N, Ikeda Y, Shimada H, Kahoud ER, Haviv S, Iwase S, Asara JM, Campbell SL, Sasaki AT. Identification of lysine methylation in the core GTPase domain by GoMADScan. PLoS One 14(8):e0219436, 2019. PMID: 31390367.
21. Kofuji S, Hirayama A, Eberhardt AO, Kawaguchi R, Sugiura Y, Sampetrean O, Ikeda Y, Warren M, Sakamoto N, Kitahara S, Yoshino H, Yamashita D, Sumita K, Wolfe K, Lange L, Ikeda S, Shimada H, Minami N, Malhotra A, Morioka S, Ban Y, Asano M, Flanary VL, Ramkissoon A, Chow LML, Kiyokawa J, Mashimo T, Lucey G, Mareninov S, Ozawa T, Onishi N, Okumura K, Terakawa J, Daikoku T, Wise-Draper T, Majd N, Kofuji K, Sasaki M, Mori M, Kanemura Y, Smith EP, Anastasiou D, Wakimoto H, Holland EC, Yong WH, Horbinski C, Nakano I, DeBerardinis RJ, Bachoo RM, Mischel PS, Yasui W, Suematsu M, Saya H, Soga T, Grummt I, Bierhoff H, Sasaki AT. IMP dehydrogenase-2 drives aberrant nucleolar activity and promotes tumorigenesis in glioblastoma. Nat Cell Biol 21(8):1003-1014, 2019. PMID: 31371825.
22. Majd NK, Metrus NR, Santos-Pinheiro F, Trevino CR, Fuller GN, Huse JT, Chung C, Ketonen L, Anderson MD, Penas-Prado M. RBM10 truncation in astroblastoma in a patient with history of mandibular ameloblastoma: A case report. Cancer Genet 231-232:41-45, 2019. PMID: 30803556.
23. Majd N, Wei X, Demopoulos A, Hormigo A, Chari A. Characterization of central nervous system multiple myeloma in the era of novel therapies. Leuk Lymphoma 57(7):1709-13, 2016. PMID: 26727654.
24. Sumita K, Lo YH, Takeuchi K, Senda M, Kofuji S, Ikeda Y, Terakawa J, Sasaki M, Yoshino H, Majd N, Zheng Y, Kahoud ER, Yokota T, Emerling BM, Asara JM, Ishida T, Locasale JW, Daikoku T, Anastasiou D, Senda T, Sasaki AT. The Lipid Kinase PI5P4Kβ Is an Intracellular GTP Sensor for Metabolism and Tumorigenesis. Mol Cell 61(2):187-98, 2016. PMID: 26774281.
25. Majd N, Sumita K, Yoshino H, Chen D, Terkawa J, Daikoku T, Curry R, Wise-Draper T, Warnick R, Guarnaschelli J, Sasaki A.. A review of the potential Utility of Mycophenolate Mofetil as a cancer therapeutic. Journal of Cancer Research, 2014.
26. Sumita K, Yoshino H, Sasaki M, Majd N, Kahoud ER, Takahashi H, Takeuchi K, Kuroda T, Lee S, Charest PG, Takeda K, Asara JM, Firtel RA, Anastasiou D, Sasaki AT. Degradation of activated K-Ras orthologue via K-Ras-specific lysine residues is required for cytokinesis. J Biol Chem 289(7):3950-9, 2014. PMID: 24338482.
27. Majd NK, Jain SK, Murphy MC, Dugas JP, Hager F, Abdulrahman R. Total skin electron beam radiation in a pediatric patient with leukemia cutis: a case report. J Pediatr Hematol Oncol 34(7):556-8, 2012. PMID: 23007342.
28. Majdzadeh N, Wang L, Morrison BE, Bassel-Duby R, Olson EN, D'Mello SR. HDAC4 inhibits cell-cycle progression and protects neurons from cell death. Dev Neurobiol 68(8):1076-92, 2008. PMID: 18498087.
29. Majdzadeh N, Morrison BE, D'Mello SR. Class IIA HDACs in the regulation of neurodegeneration. Front Biosci 13:1072-82, 2008. PMID: 17981613.
30. Morrison BE, Majdzadeh N, D'Mello SR. Histone deacetylases: focus on the nervous system. Cell Mol Life Sci 64(17):2258-69, 2007. PMID: 17530170.
31. Morrison BE, Majd NK, Zhang X, Lyles A, Bassel-Duby R, Olson EN, D'Mello SR.. Neuroprotection by histone deacetylase-related protein. Molecular and Cellular Biology 26(9), 2006. PMID: 16611996.
32. Chin PC, Majdzadeh N, D'Mello SR. Inhibition of GSK3beta is a common event in neuroprotection by different survival factors. Brain Res Mol Brain Res 137(1-2):193-201, 2005. PMID: 15950778.
33. Johnson K, Liu L, Majd NK, Chavez C, Chin PC, Morrison BE, Wang L, Park J, Chugh P, Chen HM, D'Mello SR.. Inhibition of neuronal apoptosis by the cyclin-dependent kinase inhibitor GW8510: Identification of 3' substituted indolones as a scaffold for the development of neuroprotective drugs. Journal of Neurochemistry 93(3):538-548, 2005. PMID: 15836613.

Invited Articles

1. Robertson IJ, Gregory TA, Waguespack GS, Penas-Prado M, Majd NK. Recent Therapeutic Advances in Pituitary Carcinoma. Journal of Immunotherapy and Precision Oncology 6(1), 2022.
2. Ou A, Yung WK, Majd NK.. Molecular Mechanisms of Treatment Resistance in Glioblastoma. International Journal of Molecular Sciences 22(1), 2020. PMID: 33396284.
3. Majd NK, Yung WK, de Groot JF.. The Promise of Poly(ADP-Ribose) Polymerase (PARP) Inhibitors in Gliomas. Journal of Immunotherapy and Precision Oncology 3(4):157-164, 2020. PMID: 35665372.
4. Majd NK, Kamiya-Matsuoka C, de Groot JF.. The path forward for anti-programmed cell death-1 therapy in gliomas. Curr Opin Neurol 32(6):864-871, 2019. PMID: 31567548.
5. Majd NK, de Groot JF.. Challenges and strategies for successful clinical development of immune checkpoint inhibitors in glioblastoma. Expert Opin Pharmacother 20(13):1609-1624, 2019. PMID: 31264484.
6. Majd NK, Penas-Prado M.. Updates on Management of Adult Medulloblastoma. Springer Nature 20(64), 2019.

Editorials

1. Majd N, Weathers SP, de Groot J. Are we AKT-ually getting closer to making targeted therapy successful in breast cancer brain metastases?. Neuro Oncol 21(11):1344-1345, 2019. PMID: 31515554.

Abstracts

1. Weathers S, Kamiya-Matsuoka C, Majd N, Ashu A, Thompson C, Gachimova E, Aaroe A, Patel C, Loghin M, O'Brien B, Yung WKA, Puduvalli V, de Groot J.. CTIM-23 - Safety run-in results of a phase I/II study to evaluate atezolizumab in combination with cabozantinib in patients with recurrent glioblastoma. Neuro-Oncology 25(Suppl 5):v67, 2023. e-Pub 2023.
2. Majd N, Yang L, Williford G, Alfaro-Munoz K, Pushan D, Heimberger A, Kannan K, Huse J, Bhat K, de Groot J. TMIC-58 - Alterations in glioblastoma tumor microenvironment transcriptome after treatment with pembrolizumab. Neuro-Oncology 25(Suppl 5):v291, 2023. e-Pub 2023.
3. Majd N, Yeboa DN, Weathers S, Yuan Y, Robichaux C, Al Anssari H, Gachimova E, Loghin M, Kamiya-Matsuoka C, O'Brien B, Aaroe A, Patel C, Yung WKA, Wintermark M, Gule M, Ferguson S, Puduvalli V, de Groot J.. CTNI-42 - Phase I clinical trial of peposertib plus radiation in newly diagnosed MGMT-unmethylated glioblastoma. Neuro-Oncology 25(Suppl 5):v84, 2023. e-Pub 2023.
4. Kamiya-Matsuoka C, Weathers S, Yung WKA, Loghin M, Majd N, Brown D, Langlands J, Schwartz R, Knight S, Puduvalli V, de Groot J, O'Brien B.. CTNI-78 - Evaluation of post-progression treatments after VAL-083 in recurrent and newly diagnosed GBM MGMT-unmethylated patients. Neuro-Oncology 25(Suupl 5):v95-v96, 2023. e-Pub 2023.
5. Roth P, Papadopoulos KP, Vieito M, Yang J, Majd N, Sepulveda J, Schaff L, Moreno V, Perez-Larraya JG, Micallef S, Bellon A, Mokhtar O, Imedio ER, Piggott L, Rodriguez-Freixinos V, Rodon J.. RTID-03 - A Phase 1/2 study of the WEE1 inhibitor Debio 0123 in combination with temozolomide +- radiotherapy in adults with recurrent or newly diagnosed glioblastoma. Neuro-Oncology 25(Suppl 5):v258-v259, 2023. e-Pub 2023.
6. Lam K, Lin HY, Williford G, Wathoo C, Majd N.. Ivosidenib off-label use for IDH mutant gliomas: The MD Anderson Cancer Center real life experience. Journal of Clinical Oncology 41(suppl 16), 2023.
7. Gregory T, Knight S, Aaroe A, O'Brien BJ, Patel CB, Weathers SS, Majd N, Puduvalli VK, Kamiya-Matsuoka C.. Analysis of tumor progression among patients with glioma after COVID-19 infection. Journal of Clinical Oncology 41(suppl 16), 2023.
8. Kamiya-Matsuoka C, Majd N, Harrison R, Knight S, Langlands J, Brown D, Puduvalli V.. DDDR-36. VAL-083 IN PATIENTS WITH RECURRENT GLIOBLASTOMA TREATED UNDER EXPANDED ACCESS PROGRAM. Neuro-Oncology 24(suppl 7):vii107, 2022.
9. Weathers SS, Zhu H, Knafl M, Damania A, Kamiya-Matsuoka C, Harrison RA, Lyons L, Yun C, Darbonne WC, Loghin M, Penas Prado M, Majd NK, Yung WK, O’Brien BJ, Wistuba II, Futreal A, Wargo JA, Ajami N, Woodman SE, de Groot JF.. Baseline tumor genomic and gut microbiota association with clinical outcomes in newly diagnosed glioblastoma (GBM) treated with atezolizumab in combination with temozolomide (TMZ) and radiation. American Society of Clinical Oncology 40(Suppl 16), 2022.
10. Bota DA, Badie B, Heimberger AB, Majd NK, Awadalla MS, Colerangle J, He S, Koppisetti S, van der Touw W, Hariri R, Pecora AL.. A phase I/IIa, open-label, multicenter, non-randomized clinical trial to assess the safety and efficacy of CYNK-001 in combination with recombinant human interleukin 2 in adults with recurrent resection eligible IDH1 wild-type glioblastoma (GBM). American Society of Clinical Oncology 40(Suppl 16), 2022.
11. Harrison RA, Majd NK, Johnson M, Urbauer D, Puduvalli V, Khasraw M.. Characterization of Industry Relationships in Oncology. American Society of Clinical Oncology, 2022.
12. Dasgupta PR, Lin H, Soomro ZA, Bornstein C, Alfaro-Munoz K, Yuan Y, De Groot JF, Majd NK.. Clinical and Molecular Determinants of Survival Outcomes in Glioblastoma Patients Treated with Immune Checkpoint Inhibitors. American Academy of Neurology, 2022.
13. Nantavithya C, Paulino AC, Liao K, Woodhouse KD, McGovern SL, Grosshans DR, MD, McAleer MF, Khatua S, Chintagumpala MM, Majd N, Zaky W, Yeboa DN. Observed‐to‐expected incidence ratios of second malignant neoplasms after radiation therapy for medulloblastoma: A surveillance, epidemiology, and end results analysis. American Cancer Society, 2021.
14. Weathers S, Knafl M, Cuentas EP, Espiridion BS, Hernandez S, Solis L, Wistuba I, Futreal A, Maru D, Kamiya-Matsuoka C, Harrison RA, Lyons L, Yun C, Darbonne WC, Loghin M, Penas-Prado M, Majd NK, Yung WKA, O’Brien BJ, Woodman S, de Groot JF.. Biomarker immune correlates in newly diagnosed glioblastoma (GBM) treated with atezolizumab in combination with temozolomide (TMZ) and radiation. Society for Neuro-Oncology, 2021.
15. Pham LC, Gann CN, Schumacher KM, Vlassak S, Swanson T, Highsmith K, Ou A, Clarke N, Aaroe AE, Robell LJ, O’Brien BJ, Nash S, de Groot JF, Majd NK.. Complete Response to Adjuvant Tepotinib in A Patient with Newly Diagnosed Disseminated Glioblastoma (GBM) Harboring MET Amplification. Society for Neuro-Oncology, 2021.
16. Ou A, Lin H, Bornstein C, Alfaro-Munoz KD, Yuan Y, Afshar-Khargan V, Kamiya-Matsuoka C, Majd NK.1. The Risk and Burden of Thromboembolic and Hemorrhagic Events in Patients with Malignant Glioma Receiving Bevacizumab. Society for Neuro-Oncology, 2021.
17. Aaroe A, D3CODE Team, Harrison RA, Majd NK, O'Brien BJ, Weathers SP, Loghin M, Kamiya-Matsuoka C, Yung WK, de Groot JF, Woodman K.. COVD-30 - A snapshot of the impact of COVID-19 on patients with nervous system tumors. Society for Neuro-Oncology 22(Suppl 2):ii27, 2020. e-Pub 2020.
18. Weathers SP, Kamiya-Matsuoka C, Harrison RA, Liu D, Sanqui E, Dervin S, Yun C, Loghin M, Penas-Prado M, Majd NK, Yung WKA, O’Brien BJ, de Groot J.. CTIM-11 - Phase I/II study to evaluate the safety and clinical efficacy of atezolizumab (atezo) in combination with temozolomide (TMZ) and radiation in patients with newly diagnosed glioblastoma (GBM). Society for Neuro-Oncology 22(suppl 2):ii35, 2020. e-Pub 2020.
19. Majd NK, Waguespack S, Filip J, Fu S, Penas-Prado M, Xu M, Alshawa A, Kamiya-Matsuoka C, Raza S, McCutcheon IE, Aung N.. CTIM-30 - Efficacy of Pembrolizumab in Patients with Pituitary Carcinoma: results from a phase II study. Society for Neuro-Oncology 22(Suppl 2):ii39-ii40, 2020.
20. O'Brien BJ, Penas-Prado M, Kamiya-Matsuoka C, Weathers SP, Yung WK, Loghin M, Harrison RA, Majd NK, Bacha J, Brown D, Johnson G, Langlands J, Schwartz R, Kanekal S, Steino A, Lopez L, de Groot JF.. CTNI-72 - Phase 2 study of dianhydrogalactitol (VAL-083) in patients with MGMT-unmethylated, bevacizumab-naïve glioblastoma in the recurrent and adjuvant setting. Society for Neuro-Oncology 22(Suppl 2):ii59, 2020. e-Pub 2020.
21. Shivaprasad A, Qasim M, Langford L, Fuller G, El-Naggar AK, Vishwanathan A, Tremont-Lukats I, Majd NK.. NIMG-62 - Amphetamine-associated CNS vasculitis masquerading as tumour. Society for Neuro-Oncology 22(Suppl 2):ii161-ii162, 2020. e-Pub 2020.
22. Aaroe A, Dono A, Youssef M, Alfaro-Munoz KD, Weathers SP, O'Brien BJ, Majd NK, Harrison RA, Loghin M, Soomro Z, Williford G, Fuller G, Yung WK, Yeboa D, Esquenazi Y, Ballester LY, de Groot JF, Kamiya-Matsuoka C,. PATH-05 - A retrospective study of treatment strategies and outcomes in WHO grade II and III isocitrate dehydrogenase (IDH) wild-type astrocytoma. Society for Neuro-Oncology 22(Suppl 2):ii164-ii165, 2020. e-Pub 2020.
23. Dono A, Alfaro-Munoz KD, Yan Y, Lopez-Garcia CA, Soomro Z, Williford G, Takayasu T, Roberll L, Majd NK, de Groot JF, Esquenazi Y, Kamiya-Matsuoka C, Ballester LY,. PATH-19 - Molecular, Histologic and Clinical Characteristics of Oligodendrogliomas: A Multi-institutional Retrospective Study. Society for Neuro-Oncology 22(Suppl 2):ii168, 2020. e-Pub 2020.
24. Majd NK, Rizk M, Ericson S, Grzegorzewski K, Koppisetti S, Zhu J, Kang L, He S, Mahlakoiv T, van Der Touw W, Zhang X, Habboubi N, Hariri R, Hunter K, Alfaro-Munoz KD, Heimberger AB, de Groot JF, Chi L, Srour S.. RTID-07 - Human Placental hematopoietic Stem Cell Derived Natural Killer Cells (CYNK-001) for Treatment of Recurrent Glioblastoma. Society for Neuro-Oncology 22(Suppl 2):ii194-ii195, 2020.
25. Khan S, Martinez-Ledesma E, Mittal S, Gandy K, Alfaro-Munoz KD, Majd NK, Balasubramaniyan V, de Groot JF, Khan S.. STEM-09 - Intrinsic interferon signaling regulates the cell death of glioblastoma stem cells. Society for Neuro-Oncology 22(Suppl 2):ii198, 2020. e-Pub 2020.
26. Weathers SP, Kamiya-Matsuoka C, Harrison RA, Liu DD, Dervin S, Yun C, Loghin ME, Penas-Prado M, Majd NK, Yung WKA, O'Brien BJ, de Groot JF.. Phase I/II study to evaluate the safety and clinical efficacy of atezolizumab (atezo; aPDL1) in combination with temozolomide (TMZ) and radiation in patients with newly diagnosed glioblastoma (GBM). Journal of Clinical Oncology 38(15):2511, 2020.
27. Weathers SP, Penas-Prado M, Banerfee PP, Bdiwi M, Shalm H, Alsuliman A, Shanley M, Long J, de Groot JF, O'Brien BJ, Majd NK, Harrison RA, Kamiya-Matsuoka C, Fuller GN, Chi L, Rao G, Lang FF, Shpall EJ, Rezvani K, Heimberger AB.. A phase I/II clinical trial of autologous CMV-specific T cells in glioblastoma (GBM) patients to reveal a lack of immune effector function. Journal of Clinical Oncology 38(15):2515, 2020.
28. Majd NK, Lin HY, Yuan Y, Alfaro-Munoz K, Hunter K, Heimberger AB, de Groot JF.. Evaluation of glioblastoma tumor microenvironment after treatment with pembrolizumab. Journal of Clinical Oncology 38(15):2559, 2020.
29. Majd N.. Characterization of Adult Medulloblastoma; a retrospective review of 200 patients at MD Anderson Cancer Center. Society for Neuro-Oncology Conference, 2019.
30. O'Brien B, Penas-Prado M, Kamiya-Matsuoka C, Weathers SP, Yung WK, Loghin M, Harrison R, Majd N, Bacha J, Brown D, Johnson G, Langlands J, Schwartz R, Kanekal S, Lopez L, DeGroot J.. Phase 2 study of dianhydrogalactitol (VAL-083) in patients with MGMT-unmethylated, bevacizumab-naïve glioblastoma in the recurrent and adjuvant setting. Society for Neuro-Oncology Conference 21(6):vi14-vi15, 2019.
31. Mittal S, Sen S, Khan S, McGee K, Alfaro-Munoz KD, Balasubramaniyan V, Majd NK, de Groot JF.. Complement System and Glioblastoma: an Intricate Relationship. Society for Neuro-Oncology Conference, 2019.
32. Majd N, Park S, Martinez de Kraatz M, Balasubramaniyan V, Sandeep M, Hu J, Paik J, de Groot J.. MEK inhibitors for treatment of Oligodendroglioma. American Association of Cancer Research, 2019.
33. Alfaro-Munoz K, Hallatt G, Trevino C, Majd N, Sookprasong J, Shay M, Weathers S, de Groot J, Lari B, Yu E, Jin J, Futreal A, Ravi V.. Facilitating Clinical Research Through Enabling Early Exploratory Analytics. HealthCon, 2019.
34. Mastall M, Majd N, Hess K, Fuller G, Gule-Monroe M, Huse J, Khatua S, Rao G, Wefel J, Yeboa D, Zaky W, Mahajan A, Puduvalli V, Suki D, Alfaro K, Weathers S, Harrison R, de Groot J, Penas-Prado M.. Characterization of adult medulloblastoma patients at recurrence: retrospective review of the MD Anderson Cancer Center Experience. Society for Neuro-Oncology, 2018.
35. Metrus NR, Daher A, Harrison RA, Majd N, Maraka. Analysis of Challenges to Accrual in Clinical Trials for Newly Diagnosed Glioblastoma. Society for Neuro-Oncology, 2018.
36. Mastall M, Majd N, Fuller G, Hess K, GuleMonroe M, Huse J, Khatua S, Rao G, Wefel J, Yeboa D, Zaky W, Mahajan A, Puduvalli V, Suki D, Alfaro K, Weathers S, Harrison R, de Groot J, Penas-Prado M.. Adult Medulloblastoma: analysis of use of chemotherapy in clinical practice. European Association of Neuro-Oncology, 2018.
37. Hamoud D, Majd N, Kleiman A.. Bing Neel Syndrome: Rare Complication of Rare Disease. American Neurological Association, 2018.
38. Majd N, Han D, Sasaki M, Yoshino H, Chaudhary R, Warnick R, Steckl A, Sasaki A.. Development of nanofiber-based controlled local drug delivery as a novel adjuvant modality for treatment of glioblastoma. Society for Neuro-Oncology, 2017.
39. Davalos L, Quinlan J, Baba-Ahmed N, Majd N.. Acute Heroin Related Neuropathy as a Result of Nerve compression due to Muscle Inflammation and Rhabodymyolysis; A Report of Two Cases. University of Cincinnati Neuroscience Institute Research Day, 2017.
40. Randhawa J, Yoshino H, Kobayashi T, Kofuji S, Finley K, Majd N, Malhotra A, Wise-Draper T, Yamasaki T, Shibuya S, Ogawa O, Okumura K, Sasaki A.. Dynamic role of GTP-energy metabolism in metastasis of renal cell carcinomas: Prognosis and therapeutic applications. American Society of Clinical Oncology, 2016.
41. Randhawa JS, Yoshino H, Kobayashi T, Kofuji S, Finley K, Majd NK, Malhotra A, Wise-Draper T, Yamasaki T, Shibuya S, Ogawa O, Okumura K, Sasaki A.. Dynamic role of GTP-energy metabolism in metastasis of renal cell carcinomas: Prognosis and therapeutic applications. American Society of Clinical Oncology, 2016.
42. Majd N, Neil E, Warnick R, Tew J, Hagen M, Curry R.. Recurrent aseptic meningitis in brain tumor patients; a novel perspective. Society for Neuro-Oncology, 2014.
43. Neil E, Majd N, Morris J, Karim N, Molano J, Colapietro P, Curry R.. Concurrence of gliomas in patients with multiple sclerosis; case report and literature review. Society for Neuro-Oncology, 2014.
44. Majd N, Sumita K, Yoshino H, Chen D, Sasaki A.. A novel therapeutic target for treatment of malignant brain tumors. American Academy of Neurology, 2014.
45. Majd N, Li Xiao, Demopoulos A, Chari A.. CNS involvement in multiple myeloma patients in the era of novel therapies. American Academy of Neurology, 2013.
46. Kushner T, Majd N, Siegel R, Wong S, Liverant M, Gonzales S.. Blood urea nitrogen as a predictor of development of Post-Endoscopic Retrograde Cholangiopancreatography pancreatitis: a case-control study. Digestive Disease Week, 2012.
47. Majd N, Sood V, Parapudi S, Dissanaike S.. Hypokalaemia due to an aldosterone secreting adrenal adenoma- a case report. 23rd Annual Student Research Week – Texas Tech Univ, 2011.
48. Majdzadeh NK, Wang L, Morrison BE, Bassel-Duby R, Olson EN, D'Mello SR.. HDAC4 inhibits cell-cycle progression and protects neurons from cell death. 20th Annual Student Research Week – Texas Tech Univ. Health Sciences Center, 2008.
49. Majdzadeh NK, Wang L, Morrison BE, Bassel-Duby R, Olson EN, D'Mello SR.. HDAC4 inhibits cell-cycle progression and protects neurons from cell death. Society for Neuroscience, 2007.
50. Majdzadeh NK, Wang L, Morrison BE, Bassel-Duby R, Olson EN, D'Mello SR.. Role of HDAC4 in regulation of neuronal survival. Society for Neuroscience, 2006.
51. Majdzadeh NK, Morrison BE, Bassel-Duby R, Olson EN, D'Mello SR. Role of HDAC4 and 5 in neuronal survival. Society for Neuroscience, 2004.
52. Majdzadeh NK, Dieckman G.. Characterization of carbon nanotubes. Biology and Chemistry Student Spring Symposium, Univ. of Texas at Dallas, 2003.

Book Chapters

1. Majd NK, Dasgupta PR, de Groot JF.. Immunotherapy for Neuro-oncology. In: Springer, 233-258, 2022.
2. Harrison RA, Majd NK, Tummala S, de Groot JF. Neurologic Toxicities of Immunotherapy. In: Adv Exp Med Biol, 417-429, 2021.
3. Majd NK, Dasgupta P, de Groot JF.. Immunotherapy. Advances in Experimental Medicine and Biology. In: Immunotherapy for Neuro-Oncology. Springer, 183-203, 2020.
4. Majd N., Loghin M.. Leptomeningeal Disease in Solid Cancers. In: Oncologic Critical Care, 1-19, 2018.